Ivermectin and Cancer: What the Science Really Says

For decades, ivermectin was known as one thing: a remarkably safe antiparasitic drug that has protected millions of people from diseases like river blindness and scabies. Then researchers started looking more closely at what it was actually doing inside human cells — and the findings were surprising.

Today, ivermectin is one of the most actively discussed repurposed drugs in oncology research. A 2024 systematic review in Pharmaceutics analyzed dozens of preclinical and clinical studies and concluded that ivermectin demonstrates “multi-targeted anticancer activity” across a range of cancer types [1].

What Is Drug Repurposing?

Drug repurposing — using an approved medication for a new purpose — has produced some of oncology’s most important breakthroughs. Thalidomide, once a sedative, is now a first-line treatment for multiple myeloma. Metformin, a diabetes medication, is being studied in cancer prevention trials worldwide.

Ivermectin fits this pattern. It’s been approved, used safely at scale, and now scientists are discovering it targets several of the key vulnerabilities in cancer cells.

7 Ways Ivermectin Targets Cancer Cells

1. It Blocks MDR — The “Chemo Escape” Mechanism

One of the biggest reasons cancer becomes resistant to chemotherapy is a protein called P-glycoprotein (P-gp), sometimes called the “multidrug resistance pump.” It physically pushes chemotherapy drugs out of cancer cells before they can do their job.

Ivermectin is one of the most potent known inhibitors of P-gp — even outperforming verapamil, the standard reference compound used in MDR research [2]. In practical terms, this means ivermectin may help chemotherapy drugs stay inside cancer cells longer, potentially restoring sensitivity in tumors that have become resistant.

2. It Shuts Down the Wnt/β-Catenin Pathway

The Wnt/β-catenin pathway is a key driver of cancer cell proliferation and metastasis — particularly in colorectal, breast, and stomach cancers. Ivermectin suppresses this pathway by binding to a protein called TELO2, reducing β-catenin levels and blocking its entry into the cell nucleus where it would normally activate tumor growth genes [3].

3. It Degrades PAK1 — An Oncogenic Kinase

PAK1 (p21-activated kinase 1) is overexpressed in ovarian cancer, breast cancer, lung cancer, and several other tumor types. It acts like a “master switch” for multiple pro-tumor signals. Ivermectin causes PAK1 to be tagged for destruction (ubiquitinated), effectively silencing this entire oncogenic axis [4].

4. It Triggers Immunogenic Cell Death

This may be ivermectin’s most exciting property for oncology. When cancer cells die via immunogenic cell death (ICD), they release molecular alarm signals — including ATP and HMGB1 — that alert the immune system. This can activate T-cells against the tumor.

Research published in NPJ Breast Cancer showed ivermectin promoted T-cell infiltration into immunologically “cold” breast tumors — tumors that normally evade immune detection. This theoretically makes it a natural partner for checkpoint inhibitors like pembrolizumab or balstilimab.

5. It Inhibits YAP1 in Gastric Cancer

In gastric cancer models, ivermectin suppressed YAP1 — a transcriptional co-activator that drives uncontrolled cell growth. Sensitivity to ivermectin correlated with YAP1 expression levels, suggesting this could become a predictive biomarker [8].

6. It Induces Pyroptosis in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is among the hardest subtypes to treat. A 2020 study in Cell Death & Disease found that ivermectin induced pyroptosis (an inflammatory form of programmed cell death) specifically in TNBC cells, via a caspase-1 pathway [5].

7. It Disrupts the Nuclear Transport System

Cancer cells rely on rapid nuclear-cytoplasmic shuttling of transcription factors to maintain their proliferative state. Ivermectin disrupts this transport by interfering with the importin α/β complex, potentially blocking pro-oncogenic proteins from reaching the nucleus [7].

Cancer Types Where Ivermectin Has Been Studied

Preclinical data exists across a remarkably wide range of tumors:

• Breast cancer (including TNBC and hormone-resistant subtypes)
• Colorectal cancer (Wnt pathway hyperactivation is common in ~80% of cases)
• Ovarian cancer (PAK1-dependent growth)
• Lung cancer (NSCLC and SCLC models)
• Gastric cancer (YAP1 mechanism)
• Glioblastoma (GBM — though with BBB caution)
• Chronic myeloid leukemia
• Melanoma
• Pancreatic cancer
• Prostate cancer

What Clinical Evidence Exists?

The honest answer: the clinical evidence is still early, but it is progressing.

The Cedars-Sinai Trial (NCT05318469): This is the most significant piece of ongoing clinical research. Cedars-Sinai Medical Center is running a Phase I/II study combining ivermectin with balstilimab (an anti-PD-1 immunotherapy) in patients with metastatic triple-negative breast cancer. Preliminary data published in 2025 showed the combination was safe and well-tolerated, with encouraging clinical benefit in a heavily pre-treated patient population [6].

The Observational Study (2026): A prospective cohort of 197 cancer patients taking ivermectin + mebendazole showed a Clinical Benefit Ratio of 84.4%, with 48.4% reporting tumor regression or no evidence of disease at 6 months [9].

Dosing: What’s Actually Being Used?

The standard antiparasitic dose is 150–200 mcg/kg, taken once. In oncology protocols, dosing tends to be repeated and higher. The Cedars-Sinai trial uses ivermectin on days 1–3, 8–10, and 15–17 of each 21-day cycle, reflecting a pulse-dose approach.

Important: Always take ivermectin with a fatty meal — it significantly increases bioavailability (absorption). Avoid high-concentration veterinary formulations; they are not safe for human use.

Safety Considerations

Ivermectin has an excellent safety profile at approved doses. The key risks to know:

• Neurotoxicity at high doses: Ivermectin is pumped out of the brain by P-glycoprotein. At very high doses — or in people with ABCB1 gene mutations — brain concentrations can reach toxic levels.
• Warfarin interaction: Cases of elevated INR have been reported. Patients on anticoagulants need closer monitoring.
• Veterinary formulations: Never use concentrated veterinary injectable solutions.

The Bottom Line

Ivermectin is not a replacement for oncology care. But it is a molecule with a genuinely remarkable multi-target profile, an excellent safety record at standard doses, and growing clinical interest. The combination of MDR reversal, immune activation, and direct cytotoxicity makes it unlike most single-pathway drugs.

The research community has noticed. The clinical trial pipeline is building. And for patients who are exploring every option, understanding the science is the first step.